| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Diseases | 16 | 2020 | 722 | 2.510 |
Why?
|
| Neoplasms | 39 | 2022 | 15931 | 1.770 |
Why?
|
| Pericardial Effusion | 5 | 2019 | 124 | 1.670 |
Why?
|
| Cardiac Tamponade | 3 | 2016 | 50 | 1.490 |
Why?
|
| Radiation Injuries | 9 | 2022 | 1476 | 1.460 |
Why?
|
| Cardiomyopathies | 8 | 2022 | 548 | 1.430 |
Why?
|
| Electrocardiography | 10 | 2015 | 1146 | 1.390 |
Why?
|
| Acute Coronary Syndrome | 4 | 2022 | 220 | 1.320 |
Why?
|
| Carcinoid Heart Disease | 2 | 2019 | 12 | 1.260 |
Why?
|
| Cardiovascular Diseases | 11 | 2022 | 2217 | 1.150 |
Why?
|
| Myocardial Ischemia | 6 | 2018 | 402 | 1.100 |
Why?
|
| Endocarditis | 4 | 2021 | 126 | 1.090 |
Why?
|
| Thrombolytic Therapy | 4 | 2013 | 250 | 1.090 |
Why?
|
| Fibrinolytic Agents | 3 | 2013 | 293 | 1.020 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2018 | 67 | 0.970 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2015 | 121 | 0.960 |
Why?
|
| Cardiotoxicity | 5 | 2022 | 152 | 0.930 |
Why?
|
| Myocardial Infarction | 9 | 2020 | 1154 | 0.920 |
Why?
|
| Heart Conduction System | 2 | 2015 | 160 | 0.920 |
Why?
|
| Radiotherapy | 7 | 2019 | 1858 | 0.910 |
Why?
|
| Heart Neoplasms | 2 | 2014 | 209 | 0.770 |
Why?
|
| Echocardiography | 11 | 2021 | 1219 | 0.770 |
Why?
|
| Heart Ventricles | 4 | 2018 | 837 | 0.760 |
Why?
|
| Thrombosis | 4 | 2018 | 742 | 0.760 |
Why?
|
| Radiation, Ionizing | 1 | 2020 | 190 | 0.680 |
Why?
|
| Amyloidosis | 3 | 2022 | 174 | 0.670 |
Why?
|
| Early Diagnosis | 2 | 2018 | 315 | 0.640 |
Why?
|
| Heart | 5 | 2022 | 1173 | 0.620 |
Why?
|
| Echocardiography, Doppler | 1 | 2018 | 187 | 0.570 |
Why?
|
| Myocarditis | 2 | 2024 | 177 | 0.560 |
Why?
|
| Periodicals as Topic | 2 | 2011 | 316 | 0.560 |
Why?
|
| Humans | 103 | 2024 | 270602 | 0.550 |
Why?
|
| Pulmonary Embolism | 3 | 2009 | 342 | 0.540 |
Why?
|
| Risk Assessment | 11 | 2022 | 6762 | 0.530 |
Why?
|
| Pericarditis, Constrictive | 1 | 2016 | 9 | 0.530 |
Why?
|
| Selenium | 4 | 2002 | 51 | 0.510 |
Why?
|
| Cardiovascular Agents | 3 | 2014 | 104 | 0.500 |
Why?
|
| Myocardial Perfusion Imaging | 4 | 2009 | 74 | 0.490 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2017 | 328 | 0.490 |
Why?
|
| Pericardium | 4 | 2015 | 147 | 0.490 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2011 | 1347 | 0.480 |
Why?
|
| Fibroma | 1 | 2014 | 86 | 0.460 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2010 | 212 | 0.450 |
Why?
|
| Bradycardia | 2 | 2011 | 72 | 0.450 |
Why?
|
| Aspirin | 4 | 2012 | 373 | 0.440 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 884 | 0.430 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 656 | 0.430 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 1174 | 0.420 |
Why?
|
| Thrombocytopenia | 4 | 2019 | 871 | 0.420 |
Why?
|
| Vascular Diseases | 1 | 2015 | 234 | 0.410 |
Why?
|
| Antineoplastic Agents | 9 | 2022 | 14638 | 0.400 |
Why?
|
| Risk Factors | 19 | 2022 | 17855 | 0.400 |
Why?
|
| Cardiovascular Infections | 1 | 2012 | 9 | 0.400 |
Why?
|
| Myocardial Revascularization | 1 | 2012 | 111 | 0.390 |
Why?
|
| Equipment Reuse | 1 | 2011 | 12 | 0.380 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 363 | 0.380 |
Why?
|
| Biomedical Research | 2 | 2010 | 799 | 0.370 |
Why?
|
| Editorial Policies | 1 | 2011 | 78 | 0.370 |
Why?
|
| Cardiotoxins | 1 | 2010 | 16 | 0.350 |
Why?
|
| Coronary Vasospasm | 1 | 2010 | 14 | 0.350 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 359 | 0.350 |
Why?
|
| Ticlopidine | 1 | 2010 | 49 | 0.340 |
Why?
|
| Aged | 45 | 2018 | 73534 | 0.340 |
Why?
|
| Endocarditis, Bacterial | 2 | 2012 | 152 | 0.330 |
Why?
|
| Dextrocardia | 1 | 2009 | 11 | 0.330 |
Why?
|
| Fluorouracil | 2 | 2011 | 1990 | 0.320 |
Why?
|
| Developing Countries | 1 | 2011 | 315 | 0.320 |
Why?
|
| Male | 56 | 2024 | 128395 | 0.320 |
Why?
|
| Coronary Vessels | 2 | 2017 | 606 | 0.320 |
Why?
|
| Pacemaker, Artificial | 1 | 2011 | 209 | 0.310 |
Why?
|
| Global Health | 3 | 2019 | 672 | 0.310 |
Why?
|
| Academic Medical Centers | 3 | 2015 | 682 | 0.310 |
Why?
|
| Medical History Taking | 1 | 2009 | 175 | 0.310 |
Why?
|
| Medical Records | 2 | 2009 | 441 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2020 | 5581 | 0.300 |
Why?
|
| Hemorrhage | 3 | 2010 | 724 | 0.300 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2019 | 289 | 0.290 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2008 | 83 | 0.290 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2018 | 37 | 0.290 |
Why?
|
| Embolism, Air | 1 | 2007 | 35 | 0.290 |
Why?
|
| Pericardiocentesis | 2 | 2019 | 36 | 0.290 |
Why?
|
| Aortic Valve Stenosis | 1 | 2011 | 344 | 0.280 |
Why?
|
| Incidental Findings | 1 | 2009 | 283 | 0.280 |
Why?
|
| Lung Neoplasms | 6 | 2020 | 12038 | 0.280 |
Why?
|
| Blepharoptosis | 2 | 1998 | 74 | 0.270 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2007 | 101 | 0.270 |
Why?
|
| Terminology as Topic | 1 | 2009 | 414 | 0.270 |
Why?
|
| Female | 45 | 2022 | 148790 | 0.270 |
Why?
|
| Quinazolines | 1 | 2011 | 956 | 0.270 |
Why?
|
| Middle Aged | 40 | 2024 | 90450 | 0.260 |
Why?
|
| Autonomic Nervous System Diseases | 3 | 2013 | 70 | 0.260 |
Why?
|
| Clinical Medicine | 1 | 2005 | 26 | 0.250 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2018 | 402 | 0.250 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 520 | 0.240 |
Why?
|
| Pulmonary Emphysema | 1 | 2006 | 159 | 0.240 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2006 | 164 | 0.240 |
Why?
|
| Teaching | 1 | 2006 | 247 | 0.240 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 170 | 0.240 |
Why?
|
| Ultrasonography | 5 | 2014 | 1931 | 0.230 |
Why?
|
| Incidence | 7 | 2021 | 5825 | 0.230 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 242 | 0.230 |
Why?
|
| Physical Examination | 1 | 2005 | 306 | 0.230 |
Why?
|
| Sarcoma | 1 | 2014 | 1851 | 0.220 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2020 | 288 | 0.220 |
Why?
|
| Comorbidity | 6 | 2016 | 2392 | 0.220 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 3240 | 0.220 |
Why?
|
| Antioxidants | 2 | 2000 | 519 | 0.210 |
Why?
|
| Myocardium | 4 | 2013 | 1180 | 0.210 |
Why?
|
| Heart Rate | 4 | 2015 | 744 | 0.210 |
Why?
|
| Stroke | 1 | 2011 | 1061 | 0.210 |
Why?
|
| Time Factors | 11 | 2020 | 12971 | 0.210 |
Why?
|
| Multivariate Analysis | 6 | 2015 | 4317 | 0.210 |
Why?
|
| Heart Failure | 4 | 2011 | 2324 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2009 | 7787 | 0.190 |
Why?
|
| Stroke Volume | 4 | 2016 | 550 | 0.190 |
Why?
|
| Fibrinogen | 1 | 2002 | 211 | 0.190 |
Why?
|
| Staphylococcus aureus | 2 | 2021 | 565 | 0.190 |
Why?
|
| Education, Medical | 1 | 2005 | 345 | 0.190 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 2199 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 80 | 0.190 |
Why?
|
| Retrospective Studies | 19 | 2021 | 39922 | 0.180 |
Why?
|
| Health Maintenance Organizations | 1 | 2000 | 27 | 0.180 |
Why?
|
| Cardiology | 2 | 2020 | 512 | 0.180 |
Why?
|
| Aged, 80 and over | 16 | 2018 | 31084 | 0.180 |
Why?
|
| Students, Medical | 1 | 2005 | 421 | 0.180 |
Why?
|
| Staphylococcal Infections | 2 | 2021 | 682 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 322 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 16242 | 0.170 |
Why?
|
| Combined Modality Therapy | 5 | 2018 | 9041 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2016 | 6257 | 0.170 |
Why?
|
| Aortic Aneurysm, Abdominal | 3 | 2014 | 349 | 0.170 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2014 | 327 | 0.160 |
Why?
|
| Coronary Artery Bypass | 2 | 2003 | 529 | 0.160 |
Why?
|
| Treatment Outcome | 12 | 2017 | 33811 | 0.160 |
Why?
|
| Biomarkers | 5 | 2015 | 5048 | 0.160 |
Why?
|
| Catheters, Indwelling | 1 | 2021 | 382 | 0.160 |
Why?
|
| Erdheim-Chester Disease | 1 | 2018 | 55 | 0.150 |
Why?
|
| Miosis | 1 | 1998 | 3 | 0.150 |
Why?
|
| Medical Staff, Hospital | 1 | 1999 | 122 | 0.150 |
Why?
|
| Stents | 4 | 2010 | 1002 | 0.150 |
Why?
|
| Prognosis | 11 | 2019 | 22520 | 0.150 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 751 | 0.150 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 15270 | 0.150 |
Why?
|
| Football | 1 | 1998 | 30 | 0.150 |
Why?
|
| Eye Injuries | 1 | 1998 | 51 | 0.150 |
Why?
|
| Lung | 2 | 2006 | 3284 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2013 | 501 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2015 | 2300 | 0.140 |
Why?
|
| Ethmoid Sinus | 1 | 1997 | 27 | 0.140 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2018 | 149 | 0.140 |
Why?
|
| Logistic Models | 3 | 2015 | 3429 | 0.140 |
Why?
|
| Tachycardia, Sinus | 1 | 2016 | 12 | 0.140 |
Why?
|
| Anthracyclines | 3 | 2008 | 339 | 0.140 |
Why?
|
| Hydrocephalus, Normal Pressure | 1 | 1996 | 6 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 155 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2018 | 142 | 0.130 |
Why?
|
| Thromboembolism | 2 | 2008 | 150 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 397 | 0.130 |
Why?
|
| Survival Rate | 7 | 2021 | 12527 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 3707 | 0.130 |
Why?
|
| Atenolol | 1 | 1995 | 45 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 4964 | 0.130 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 73 | 0.130 |
Why?
|
| Urinary Incontinence | 1 | 1996 | 149 | 0.120 |
Why?
|
| Medical Oncology | 2 | 2022 | 1464 | 0.120 |
Why?
|
| Adult | 18 | 2018 | 81960 | 0.120 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 563 | 0.120 |
Why?
|
| Accidental Falls | 1 | 1996 | 141 | 0.120 |
Why?
|
| Fatal Outcome | 2 | 2010 | 818 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2016 | 311 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2020 | 1151 | 0.110 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1997 | 285 | 0.110 |
Why?
|
| Palliative Care | 1 | 2005 | 2175 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2020 | 1581 | 0.110 |
Why?
|
| Texas | 5 | 2021 | 6445 | 0.110 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1995 | 201 | 0.110 |
Why?
|
| Troponin I | 1 | 2014 | 131 | 0.110 |
Why?
|
| Amyloid | 1 | 2014 | 91 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2015 | 176 | 0.110 |
Why?
|
| Iron Overload | 1 | 2013 | 33 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2016 | 685 | 0.110 |
Why?
|
| Helicobacter pylori | 1 | 2002 | 1411 | 0.100 |
Why?
|
| Helicobacter Infections | 1 | 2002 | 1329 | 0.100 |
Why?
|
| United Kingdom | 2 | 2005 | 284 | 0.100 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 147 | 0.100 |
Why?
|
| Hospitalization | 2 | 2018 | 2170 | 0.100 |
Why?
|
| DNA Damage | 1 | 2020 | 1991 | 0.100 |
Why?
|
| Cause of Death | 1 | 2015 | 781 | 0.100 |
Why?
|
| Tomography, Optical Coherence | 1 | 2017 | 552 | 0.100 |
Why?
|
| Decision Trees | 1 | 2012 | 180 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 5099 | 0.100 |
Why?
|
| Action Potentials | 1 | 2015 | 588 | 0.100 |
Why?
|
| Parenteral Nutrition, Home | 2 | 2002 | 11 | 0.100 |
Why?
|
| Platelet Count | 2 | 2010 | 488 | 0.100 |
Why?
|
| Pakistan | 1 | 2011 | 76 | 0.090 |
Why?
|
| Melphalan | 1 | 2014 | 879 | 0.090 |
Why?
|
| Mass Screening | 1 | 2019 | 1547 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 4964 | 0.090 |
Why?
|
| Coronary Disease | 2 | 2007 | 741 | 0.090 |
Why?
|
| Parenteral Nutrition, Total | 2 | 2001 | 139 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 214 | 0.090 |
Why?
|
| Relaxation Therapy | 1 | 2010 | 21 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2020 | 2178 | 0.090 |
Why?
|
| Frail Elderly | 1 | 2011 | 124 | 0.090 |
Why?
|
| Capecitabine | 1 | 2011 | 390 | 0.090 |
Why?
|
| Melena | 1 | 2010 | 9 | 0.090 |
Why?
|
| Coronary Angiography | 2 | 2017 | 537 | 0.090 |
Why?
|
| Coronary Circulation | 2 | 2009 | 240 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2017 | 13413 | 0.090 |
Why?
|
| Disease Management | 1 | 2016 | 1092 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 586 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 316 | 0.090 |
Why?
|
| Prodrugs | 1 | 2011 | 226 | 0.090 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2011 | 398 | 0.080 |
Why?
|
| Survival | 1 | 2010 | 183 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1337 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1307 | 0.080 |
Why?
|
| Platelet Transfusion | 1 | 2010 | 166 | 0.080 |
Why?
|
| Drug-Eluting Stents | 1 | 2010 | 77 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 453 | 0.080 |
Why?
|
| HIV Infections | 1 | 2001 | 2155 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 898 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 4838 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 306 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 273 | 0.080 |
Why?
|
| Heart Septal Defects | 1 | 2009 | 48 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 165 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2011 | 352 | 0.080 |
Why?
|
| Torsades de Pointes | 1 | 2008 | 11 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 1944 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2020 | 5673 | 0.070 |
Why?
|
| Young Adult | 6 | 2018 | 22219 | 0.070 |
Why?
|
| Troponin | 1 | 2007 | 85 | 0.070 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 1162 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 87 | 0.070 |
Why?
|
| Atrial Fibrillation | 3 | 2014 | 727 | 0.070 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2011 | 449 | 0.070 |
Why?
|
| Affective Symptoms | 1 | 2006 | 86 | 0.070 |
Why?
|
| Animals | 5 | 2021 | 61346 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 477 | 0.070 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2006 | 69 | 0.070 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2007 | 98 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 1485 | 0.070 |
Why?
|
| Auscultation | 1 | 2005 | 8 | 0.070 |
Why?
|
| Intracranial Embolism | 1 | 2006 | 40 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2011 | 1042 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2011 | 1389 | 0.060 |
Why?
|
| Depression | 1 | 2016 | 1733 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 4006 | 0.060 |
Why?
|
| Diagnosis | 1 | 2005 | 35 | 0.060 |
Why?
|
| Radiation Oncology | 1 | 2011 | 558 | 0.060 |
Why?
|
| Age Factors | 3 | 2009 | 5441 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2011 | 823 | 0.060 |
Why?
|
| Adolescent | 5 | 2018 | 32684 | 0.060 |
Why?
|
| Carcinoma | 1 | 1997 | 2610 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2012 | 1246 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 333 | 0.060 |
Why?
|
| Contraindications | 1 | 2005 | 153 | 0.060 |
Why?
|
| Angiography | 1 | 2006 | 349 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 4493 | 0.060 |
Why?
|
| Liposomes | 1 | 2007 | 702 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2015 | 9281 | 0.060 |
Why?
|
| Canada | 1 | 2005 | 441 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 380 | 0.060 |
Why?
|
| Heparin | 1 | 2006 | 343 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 2343 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 3 | 2008 | 4468 | 0.060 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2009 | 417 | 0.060 |
Why?
|
| United States | 4 | 2020 | 15827 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 2394 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2014 | 7046 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 4969 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 2272 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 542 | 0.050 |
Why?
|
| Liver | 1 | 2013 | 3056 | 0.050 |
Why?
|
| Hypogonadism | 1 | 2006 | 278 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2005 | 212 | 0.050 |
Why?
|
| Diet, Fat-Restricted | 1 | 2003 | 52 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 663 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2011 | 2376 | 0.050 |
Why?
|
| Multimodal Imaging | 2 | 2018 | 551 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 2325 | 0.050 |
Why?
|
| Coronary Restenosis | 1 | 2002 | 31 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2002 | 93 | 0.050 |
Why?
|
| Omeprazole | 1 | 2002 | 109 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 69 | 0.050 |
Why?
|
| Breath Tests | 1 | 2002 | 199 | 0.050 |
Why?
|
| Patient Selection | 1 | 2010 | 2028 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2008 | 1554 | 0.050 |
Why?
|
| Amoxicillin | 1 | 2002 | 122 | 0.050 |
Why?
|
| Foreign-Body Migration | 1 | 2002 | 122 | 0.050 |
Why?
|
| Ribose | 1 | 2021 | 32 | 0.050 |
Why?
|
| Renal Artery | 1 | 2002 | 86 | 0.050 |
Why?
|
| Penicillins | 1 | 2002 | 170 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2002 | 108 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2002 | 111 | 0.050 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2002 | 77 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2021 | 100 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2003 | 187 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 162 | 0.050 |
Why?
|
| Contrast Media | 1 | 2007 | 1505 | 0.050 |
Why?
|
| National Health Programs | 1 | 2000 | 39 | 0.040 |
Why?
|
| Feedback | 1 | 2021 | 224 | 0.040 |
Why?
|
| Arteriovenous Malformations | 1 | 2000 | 66 | 0.040 |
Why?
|
| Fatigue | 1 | 2006 | 1282 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 732 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2000 | 94 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5595 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 3190 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2000 | 160 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 417 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 4053 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2000 | 239 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 248 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2000 | 309 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 2656 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2002 | 618 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 10267 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2014 | 605 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 718 | 0.030 |
Why?
|
| Systole | 1 | 2016 | 217 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2014 | 1430 | 0.030 |
Why?
|
| Bile Reflux | 1 | 1995 | 7 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2002 | 588 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2006 | 1776 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 10713 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 1995 | 184 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2000 | 605 | 0.030 |
Why?
|
| Exercise | 1 | 2003 | 1209 | 0.030 |
Why?
|
| Mitochondria | 1 | 2021 | 1292 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2000 | 834 | 0.030 |
Why?
|
| Memory Disorders | 1 | 1996 | 286 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2021 | 4907 | 0.030 |
Why?
|
| Smoking | 2 | 2016 | 2549 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2013 | 72 | 0.030 |
Why?
|
| Fluorine Radioisotopes | 1 | 2014 | 140 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1233 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 9460 | 0.030 |
Why?
|
| Gastroenterology | 1 | 1995 | 202 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 881 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 636 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 1995 | 368 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 4020 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2010 | 2856 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 709 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1996 | 347 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1996 | 517 | 0.020 |
Why?
|
| Quality of Life | 1 | 2005 | 4798 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2316 | 0.020 |
Why?
|
| Prevalence | 2 | 2011 | 3394 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 907 | 0.020 |
Why?
|
| Parasympathetic Nervous System | 1 | 2010 | 26 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2000 | 215 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6501 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 2209 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 206 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 2064 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 159 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2010 | 87 | 0.020 |
Why?
|
| Growth Disorders | 1 | 2000 | 223 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1341 | 0.020 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 165 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1260 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2000 | 616 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 999 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 4878 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2007 | 73 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2000 | 552 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 448 | 0.020 |
Why?
|
| Body Weight | 1 | 2000 | 1287 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 281 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 2374 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2007 | 309 | 0.020 |
Why?
|
| Razoxane | 1 | 2004 | 22 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2010 | 1038 | 0.010 |
Why?
|
| Dipyridamole | 1 | 2003 | 41 | 0.010 |
Why?
|
| Emotions | 1 | 2006 | 558 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 5157 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 3048 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 3906 | 0.010 |
Why?
|
| Disease Progression | 1 | 2014 | 6867 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7912 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 5238 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2002 | 192 | 0.010 |
Why?
|
| Splanchnic Circulation | 1 | 2002 | 56 | 0.010 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 626 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 334 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 2492 | 0.010 |
Why?
|
| Sepsis | 1 | 2007 | 673 | 0.010 |
Why?
|
| Rats | 1 | 2000 | 6396 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 6193 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2000 | 105 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 1186 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 370 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 35413 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2002 | 529 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2007 | 3145 | 0.010 |
Why?
|
| Life Style | 1 | 2003 | 616 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 14021 | 0.010 |
Why?
|
| Weight Loss | 1 | 2003 | 628 | 0.010 |
Why?
|
| Reoperation | 1 | 2002 | 1389 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 1956 | 0.010 |
Why?
|
| Hypoxia | 1 | 2000 | 470 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2000 | 7311 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 3491 | 0.010 |
Why?
|
| Gastric Acidity Determination | 1 | 1995 | 19 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 2803 | 0.010 |
Why?
|
| Child | 2 | 2000 | 30558 | 0.010 |
Why?
|
| Posture | 1 | 1995 | 206 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1995 | 604 | 0.010 |
Why?
|
| Eating | 1 | 1995 | 439 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1995 | 515 | 0.010 |
Why?
|
| Barrett Esophagus | 1 | 1995 | 560 | 0.010 |
Why?
|